CTNM – contineum therapeutics, inc. - common stock (US:NASDAQ)

News

Contineum Therapeutics (NASDAQ:CTNM) was downgraded by analysts at Wall
Contineum Therapeutics (NASDAQ:CTNM) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $14.00 price target on the stock, down previously from $23.00.
Contineum Therapeutics (NASDAQ:CTNM) was upgraded by analysts at Wall St
Contineum Therapeutics (NASDAQ:CTNM) was downgraded by analysts at Wall
Contineum Therapeutics stock drops as company prices upsized $90 million offering [Seeking Alpha]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com